Cost-Effectiveness Thresholds: the Past, the Present and the Future

Resolving the “Cost-Effective but Unaffordable” Paradox: Estimating the Health Opportunity Costs of Nonmarginal Budget Impacts

(2018) James Lomas et al.   VALUE IN HEALTH

Use and Misuse of Cost-Effectiveness Analysis Thresholds in Low- and Middle-Income Countries: Trends in Cost-per-DALY Studies

(2018) Ashley A. Leech et al.   VALUE IN HEALTH

Estimating the Reference Incremental Cost-Effectiveness Ratio for the Australian Health System

(2017) Laura Catherine Edney et al.   PHARMACOECONOMICS

Determination of Cost-Effectiveness Threshold for Health Care Interventions in Malaysia

(2017) Yen Wei Lim et al.   VALUE IN HEALTH

Developing a Value Framework: The Need to Reflect the Opportunity Costs of Funding Decisions

(2017) Mark Sculpher et al.   VALUE IN HEALTH

Cost-Effectiveness Thresholds in Global Health: Taking a Multisectoral Perspective

(2017) Michelle Remme et al.   VALUE IN HEALTH

A Systematic Review of Cost-Effectiveness Studies Reporting Cost-per-DALY Averted

(2017) Peter J. Neumann et al.   PLoS One

Cost–effectiveness thresholds: pros and cons

(2016) Melanie Y Bertram et al.   BULLETIN OF THE WORLD HEALTH ORGANIZATION

Incorporating Demand and Supply Constraints into Economic Evaluations in Low-Income and Middle-Income Countries

(2016) Anna Vassall et al.   HEALTH ECONOMICS

Understanding and improving the one and three times GDP per capita cost-effectiveness thresholds

(2016) Lisa A Robinson et al.   HEALTH POLICY AND PLANNING

Recommendations for Conduct, Methodological Practices, and Reporting of Cost-effectiveness Analyses

(2016) Gillian D. Sanders et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Determinants of Change in the Cost-effectiveness Threshold

(2016) Mike Paulden et al.   MEDICAL DECISION MAKING

On the Estimation of the Cost-Effectiveness Threshold: Why, What, How?

(2016) Laura Vallejo-Torres et al.   VALUE IN HEALTH

Country-Level Cost-Effectiveness Thresholds: Initial Estimates and the Need for Further Research

(2016) Beth Woods et al.   VALUE IN HEALTH

Multiple Criteria Decision Analysis for Health Care Decision Making—Emerging Good Practices: Report 2 of the ISPOR MCDA Emerging Good Practices Task Force

(2016) Kevin Marsh et al.   VALUE IN HEALTH

Are current ICER thresholds outdated? Valuing medicines in the era of personalized healthcare

(2016) Pricivel Carrera et al.   Expert Review of Pharmacoeconomics & Outcomes Research

Cost-Effectiveness and Budget Impact of Hepatitis C Virus Treatment With Sofosbuvir and Ledipasvir in the United States

(2015) Jagpreet Chhatwal et al.   ANNALS OF INTERNAL MEDICINE

Methods for the estimation of the National Institute for Health and Care Excellence cost-effectiveness threshold

(2015) Karl Claxton et al.   HEALTH TECHNOLOGY ASSESSMENT

Should the Lambda (λ) Remain Silent?

(2015) Hossein Haji Ali Afzali et al.   PHARMACOECONOMICS

The Irish Cost-Effectiveness Threshold: Does It Support Rational Rationing or Might It Lead to Unintended Harm of Ireland’s Health System?

(2015) JF O’Mahony et al.   VALUE IN HEALTH

Systematic overview of cost–effectiveness thresholds in ten countries across four continents

(2015) Ruth Schwarzer et al.   Journal of Comparative Effectiveness Research

Design, Implementation, and First-Year Outcomes of a Value-Based Drug Formulary

(2015) Sean D. Sullivan et al.   Journal of Managed Care & Specialty Pharmacy

Thresholds for the cost–effectiveness of interventions: alternative approaches

(2015) Elliot Marseille et al.   BULLETIN OF THE WORLD HEALTH ORGANIZATION

A Systematic Review of Studies Eliciting Willingness-to-Pay per Quality-Adjusted Life Year: Does It Justify CE Threshold?

(2015) Khachapon Nimdet et al.   PLoS One

CAUSES FOR CONCERN: IS NICE FAILING TO UPHOLD ITS RESPONSIBILITIES TO ALL NHS PATIENTS?

(2014) Karl Claxton et al.   HEALTH ECONOMICS

Updating Cost-Effectiveness — The Curious Resilience of the $50,000-per-QALY Threshold

(2014) Peter J. Neumann et al.   NEW ENGLAND JOURNAL OF MEDICINE

Resource Modelling: The Missing Piece of the HTA Jigsaw?

(2014) Praveen Thokala et al.   PHARMACOECONOMICS

Can the Real Opportunity Cost Stand Up: Displaced Services, the Straw Man Outside the Room

(2014) Simon Eckermann et al.   PHARMACOECONOMICS

Are Current Cost-Effectiveness Thresholds for Low- and Middle-Income Countries Useful? Examples from the World of Vaccines

(2014) A. T. Newall et al.   PHARMACOECONOMICS

NICE’s Cost-Effectiveness Range: Should it be Lowered?

(2014) J. P. Raftery   PHARMACOECONOMICS

NICE's end of life decision making scheme: impact on population health

(2013) M. Collins et al.   BMJ-British Medical Journal

Using threshold values for cost per quality-adjusted life-year gained in healthcare decisions

(2011) Irina Cleemput et al.   INTERNATIONAL JOURNAL OF TECHNOLOGY ASSESSMENT IN HEALTH CARE

Value-Based Approaches to Healthcare Systems and Pharmacoeconomics Requirements in Asia

(2010) Isao Kamae   PHARMACOECONOMICS

Comments on “Simoens, S. Health Economic Assessment: A Methodological Primer. Int. J. Environ. Res. Public Health 2009, 6, 2950-2966”—New Zealand in Fact Has No Cost-Effectiveness Threshold

(2010) Scott Metcalfe et al.   International Journal of Environmental Research and Public Health

Cost Effectiveness in Low- and Middle-Income Countries

(2009) Samuel D. Shillcutt et al.   PHARMACOECONOMICS

Health Economic Assessment: A Methodological Primer

(2009) Steven Simoens   International Journal of Environmental Research and Public Health

The NICE Cost-Effectiveness Threshold

(2008) Christopher McCabe et al.   PHARMACOECONOMICS